Despite clear evidence of the glutamatergic system’s role in neurodegeneration (Maragos et al., 1987; Greenamyre et al., 1988; Butterfield and Pocernich, 2003; Yeung et al., 2020a,b, 2021; Kwakowsky et al., 2021), the expression of EAAT2 is yet to be explored in AD. This evidence concerns the gene SLC1A2 and Alzheimer disease.